These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25771470)

  • 1. Increasing frequency of Pseudomonas aeruginosa infections during tigecycline use.
    Ulu-Kilic A; Alp E; Altun D; Cevahir F; Kalın G; Demiraslan H
    J Infect Dev Ctries; 2015 Mar; 9(3):309-12. PubMed ID: 25771470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nosocomial infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: molecular epidemiology, risk factors, clinical features and outcomes.
    Lucena A; Dalla Costa LM; Nogueira KS; Matos AP; Gales AC; Paganini MC; Castro ME; Raboni SM
    J Hosp Infect; 2014 Aug; 87(4):234-40. PubMed ID: 25027563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.
    Yakupogullari Y; Otlu B; Dogukan M; Gursoy C; Korkmaz E; Kizirgil A; Ozden M; Durmaz R
    Am J Infect Control; 2008 Dec; 36(10):e13-8. PubMed ID: 19084158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated approach to control a prolonged outbreak of multidrug-resistant Pseudomonas aeruginosa in an intensive care unit.
    Knoester M; de Boer MG; Maarleveld JJ; Claas EC; Bernards AT; de Jonge E; van Dissel JT; Veldkamp KE
    Clin Microbiol Infect; 2014 Apr; 20(4):O207-15. PubMed ID: 24707852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for multidrug-resistant Pseudomonas aeruginosa nosocomial infection.
    Defez C; Fabbro-Peray P; Bouziges N; Gouby A; Mahamat A; Daurès JP; Sotto A
    J Hosp Infect; 2004 Jul; 57(3):209-16. PubMed ID: 15236849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practice-based observational study identifying factors associated with the use of high-dose tigecycline in the treatment of secondary peritonitis in severely ill patients.
    Maseda E; Suárez-de-la-Rica A; Anillo V; Salgado P; Tamayo E; García-Bernedo CA; Ramasco F; Villagrán MJ; López-Tofiño A; Giménez MJ; Granizo JJ; Hernández-Gancedo C; Aguilar L; Gilsanz F
    Rev Esp Quimioter; 2015 Feb; 28(1):47-53. PubMed ID: 25690145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
    Yetkin G; Otlu B; Cicek A; Kuzucu C; Durmaz R
    Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality.
    Tumbarello M; Repetto E; Trecarichi EM; Bernardini C; De Pascale G; Parisini A; Rossi M; Molinari MP; Spanu T; Viscoli C; Cauda R; Bassetti M
    Epidemiol Infect; 2011 Nov; 139(11):1740-9. PubMed ID: 21226988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients.
    Balandin Moreno B; Fernández Simón I; Pintado García V; Sánchez Romero I; Isidoro Fernández B; Romera Ortega MA; Alcántara Carmona S; Pérez Redondo M; Galdos Anuncibay P
    Scand J Infect Dis; 2014 Mar; 46(3):175-80. PubMed ID: 24354959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.
    Aloush V; Navon-Venezia S; Seigman-Igra Y; Cabili S; Carmeli Y
    Antimicrob Agents Chemother; 2006 Jan; 50(1):43-8. PubMed ID: 16377665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Differences in the use of tigecycline between ICU patients and non-ICU patients].
    Alvarez-Lerma F; Blanco L; Rodríguez JA; Grau S; Conde-Estévez D; Luque S
    Rev Esp Quimioter; 2010 Jun; 23(2):63-71. PubMed ID: 20559603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tigecycline use in serious nosocomial infections: a drug use evaluation.
    Bassetti M; Nicolini L; Repetto E; Righi E; Del Bono V; Viscoli C
    BMC Infect Dis; 2010 Sep; 10():287. PubMed ID: 20920273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies.
    Bassetti M; Eckmann C; Bodmann KF; Dupont H; Heizmann WR; Montravers P; Guirao X; Capparella MR; Simoneau D; Sánchez García M
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii5-14. PubMed ID: 23772047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nosocomial cross-transmission of Pseudomonas aeruginosa between patients in a tertiary intensive care unit.
    Mayank D; Anshuman M; Singh RK; Afzal A; Baronia AK; Prasad KN
    Indian J Pathol Microbiol; 2009; 52(4):509-13. PubMed ID: 19805958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem-resistant Pseudomonas aeruginosa infection at a medical-surgical intensive care unit: risk factors and mortality.
    Furtado GH; Bergamasco MD; Menezes FG; Marques D; Silva A; Perdiz LB; Wey SB; Medeiros EA
    J Crit Care; 2009 Dec; 24(4):625.e9-14. PubMed ID: 19592213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of 1,025 severely ill patients with complicated infections in a German multicenter study: safety profile and efficacy of tigecycline in different treatment modalities.
    Bodmann KF; Heizmann WR; von Eiff C; Petrik C; Löschmann PA; Eckmann C
    Chemotherapy; 2012; 58(4):282-94. PubMed ID: 23052187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies.
    Eckmann C; Montravers P; Bassetti M; Bodmann KF; Heizmann WR; Sánchez García M; Guirao X; Capparella MR; Simoneau D; Dupont H
    J Antimicrob Chemother; 2013 Jul; 68 Suppl 2():ii25-35. PubMed ID: 23772043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Acinetobacter baumannii and meropenem-resistant Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-2009 study.
    McCracken M; Mataseje LF; Loo V; Walkty A; Adam HJ; Hoban DJ; Zhanel GG; Mulvey MR;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):335-41. PubMed ID: 21353962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
    Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
    J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.